Efficacy of COVID-19 Vaccines in Real-World Settings Even Better Than Expected, Fauci Says
Anthony Fauci, MD, told attendees at the ATS 2021 International Conference that the real-world evidence of vaccines against SARS-CoV-2, the virus that causes COVID-19, is even better than expected.
Anthony Fauci, MD, highlighted this weekend that the real-world evidence of vaccines against SARS-CoV-2, the virus that causes COVID-19, is even better than expected.
The head of the National Institute of Allergy and Infectious Diseases and chief medical advisor to President Joe Biden also reiterated the administration’s goal of having 70% of US adults inoculated with at least 1 dose of a COVID-19 vaccine by July 4.
During a prerecorded speech to kick off the
He called it “the most devastating pandemic of a respiratory illness in the last 102 years.”
Estimates of illness and death—both globally and in the United States—are likely undercounted, he repeatedly emphasized. Worldwide, about 160 million have been infected and 3.3 million have died; US deaths are close to 580,000 and infections have surpassed 30 million.
The United States has yet to get its baseline count of infection down to a low level, as each of the 3 deadly surges over the past year left the country worse off than before. Currently, the number of daily infections has dropped to about 40,000 a day down from 60,000 a few weeks ago.
He contrasted that with Israel, which implemented a very robust vaccination program and now has few infections.
Referring to a
Clinical US trials of the Pfizer/BioNTech and Moderna vaccines showed 95% and 94.1% efficacy, he said. The Johnson & Johnson vaccine, which was tested in the United States, Brazil, and South Africa, had 66% efficacy overall and 85% efficacy against severe disease.
"Now, usually, as many of you know, the effectiveness in the real world is often not as good as the efficacy in the pristine conditions of a clinical trial," Fauci said. "We have found just the opposite with COVID-19 vaccines, where effectiveness is easily as good, if not better, in the real world setting."
He cited a study of more than 23,000 employees of the University of Texas Southwestern Medical Center in Dallas, where vaccinations began December 15, 2020. There was just a 0.05% infection rate among workers who were fully immunized, he said.
Another study looked at the efficacy of vaccines in 8 US locations of close to 4000 essential and frontline health care workers. There were just 3 polymerase chain reaction (PCR)-confirmed infections during 78,902 person-days with full immunization (0.04/1000 person-days).
Fauci also referenced a study published in
The campaign began around the time of a surge in SARS-CoV-2 infections in Israel that resulted in a nationwide lockdown on December 27. Additional lockdowns were implemented on January 8, 2021. The country began a phased reopening on February 7 and February 21, 2021, and the lockdown was lifted on March 7.
The number of infections plummeted as vaccinations became widespread, and the authors of the study attributed the decline to the campaign, rather than the lockdown. Indeed, Fauci noted that the number of cases kept falling even as the country reopened.
The variant in Israel, B.1.1.7, is now the dominant variant here, he said. The efficacy of the vaccine stretches across age groups and is 97.5% effective at preventing severe or critical illness and 96.7% effective at preventing COVID-19 deaths.
Fauci also used the example of Qatar, where the vaccine was 100% effective at preventing death from the South African B.1.351 variant, according to another study.
This all boils down to a "race" between the virus and the vaccines, Fauci said.
"If we vaccinate the overwhelming proportion of our population, we will without a doubt be able to crush the outbreak in the same way as we have done with other viral-borne diseases like measles, smallpox, and polio. So the message is, get vaccinated."
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025